Startup
Exciva
Startup · Heidelberg, Germany
Clinical-stage biotech developing therapeutics for neuropsychiatric disorders. Lead program Deraphan targets agitation and aggression in Alzheimer's disease dementia and is in Phase 2/3. Raised EUR 51M Series B in 2026.
Connection map
Affiliation
Drag nodes to rearrange · scroll or pinch to zoom · click a node to open it